Managed Access Programs for INC280, Capmatinib
Novartis
Novartis
AstraZeneca
Intima Bioscience, Inc.
Tizona Therapeutics, Inc
Second Life Therapeutics
Pfizer
Lantern Pharma Inc.
Tango Therapeutics, Inc.
Alaunos Therapeutics
Turning Point Therapeutics, Inc.
Pfizer
BerGenBio ASA
Alaunos Therapeutics
Novartis
Celltrion
Novartis
Janssen Research & Development, LLC
Novartis
Novartis
Yuhan Corporation
Novartis
Imugene Limited
Geneplus-Beijing Co. Ltd.
Turning Point Therapeutics, Inc.
Ikena Oncology
Novartis
Multitude Therapeutics Inc.
Cantargia AB
Innovent Biologics (Suzhou) Co. Ltd.
Helix BioPharma Corporation
Novartis
MacroGenics
Bayer
Novartis
Novartis
SpeciCare
Novartis
Morphotek
Lumos Pharma
Geneplus-Beijing Co. Ltd.
Novartis
Novartis
Geneplus-Beijing Co. Ltd.
Bayer
Hoffmann-La Roche
Myriad Genetic Laboratories, Inc.
Pathway Genomics
Esanex Inc.
Endocyte
AstraZeneca